Updates to our COVID-19 management guidelines

In anticipation of a possible surge in hospitalizations and taking into account recent evidence, (and limited supplies of some therapeutics) we are delighted to present our revised (v9) guidelines! Main changes compared to previous version are highlighted in "SUMMARY of changes" . As always, these guidelines are the product of thoughtful discussions between ID and pharmacy experts, with input from a multidisciplinary group of colleagues.

HAPPY HOLIDAY SEASON to all, from the ASP team!!

Recent Posts

See All

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar

Correction in Antifungal prophylaxis for high-risk (immunocompromised)

Correction made for Heart transplant and Lung transplant recipients: both anti-mold AND anti-PJP prophylaxis recommended.

NEW UPDATE: *Change in process for outpatient COVID-19 management*

To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service ra

** Updates to our COVID-19 management guidelines **

Recent Posts

Updates to our COVID-19 management guidelines